Stoichiometry and conditional stability constants of Cu(II) or Zn(II) clioquinol complexes; implications for Alzheimer's and Huntington's disease therapy

NeuroToxicology

Volumn 28, Issue 3, 2007, Pages 445-449

  Ferrada, Evandro ^a   Arancibia, Verónica ^b   Loeb, Bárbara ^b   Norambuena, Ester ^c   Olea Azar, Claudio ^d   Huidobro Toro, J Pablo ^a  

^a UNIVERSIDAD ANDRÉS BELLO   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^c UMCE   (Chile)

^d UNIVERSITY OF CHILE   (Chile)

Author keywords

Alzheimer's and Hungtington's diseases; Clioquinol; Clioquinol complexes; Cu(II); Neurodegenerative diseases; Oxine; Zn(II)

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMYLOID BETA PROTEIN; BUFFER; CALCIUM ION; CLIOQUINOL; CUPRIC ION; HUNTINGTIN; MAGNESIUM ION; PURINE P2X RECEPTOR; ZINC ION;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOASSAY; CONTROLLED STUDY; EXCITABILITY; HUNTINGTON CHOREA; NONHUMAN; POLAROGRAPHY; PRIORITY JOURNAL; PROTEIN DEGRADATION; SPECTROSCOPY; STOICHIOMETRY; ULTRAVIOLET RADIATION;

ADENOSINE TRIPHOSPHATE; ALGORITHMS; ALZHEIMER DISEASE; ANIMALS; CHEMISTRY, PHYSICAL; CLIOQUINOL; COPPER; ELECTROPHYSIOLOGY; HUMANS; HUNTINGTON DISEASE; ION CHANNEL GATING; MICROINJECTIONS; OOCYTES; POLAROGRAPHY; RECEPTORS, PURINERGIC P2; SOLUTIONS; SPECTROPHOTOMETRY, ULTRAVIOLET; XENOPUS LAEVIS; ZINC;

EID: 34249786569     PISSN: 0161813X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuro.2007.02.004     Document Type: Article

References (21)

1. 4 receptor. J Neurochem 74 (2000) 1529
2. Angel I., Bar A., Horovitz T., Taler G., Krakosvky M., Retnisky D., et al. Metal ion chelation in neurodegenerative disorders. Drug Dev Res 56 (2002) 300
3. Bush A.I. Metal complexing agents as therapies for Alzheimer's disease. Neurobiol Aging 23 (2002) 1031
4. Bush A.I. The metallobiology of Alzheimer's disease. Trends Neurosci 4 (2003) 207
5. 7 receptors. J Neurochem 80 (2002) 626
6. Croot P.L., Moffett J.W., and Luther GW. Polarographic determination of half-wave potentials for copper organic complexes in sea water. Mar Chem 67 (1999) 219
7. Cheatum C.M., Heckscher M.M., and Crim F.F. Excited-state dynamics in 8-hydroxyquinoline dimers. Chem Phys Lett 349 (2001) 37
8. Di Vaira C., Bazzicalupi C., Orioli P., Messori L., Bruni B., and Zatta P. Clioquinol a drug for Alzheimer's disease specifically interfering with brain metal metabolism: structural characterization of its zinc(II) and copper(II) complexes. Inorg Chem 43 (2004) 3795
9. Johnston W.D., and Freiser H. Structure and behavior of organic analytical reagents. III. Stability of chelates of 8-hydroxyquinoline and analogous reagents. J Am Chem Soc 74 (1952) 5239
10. Lane T.J., Sam C.S., and Kandathil A.J. Chelate stabilities of certain oxine-type compounds. J Am Chem Soc 82 (1960) 4462
11. Lorca R.A., Chacon M., Barria M.I., Inestrosa N.C., and Huidobro-Toro J.P. The human prion octarepeat fragment prevents and reverses the inhibitory action of copper in the P2X4 receptor without modifying the zinc action. J Neurochem 85 (2003) 709
12. López R., Boys D., Loeb B., and Zuloaga F. Synthesis, crystal structure, molecular orbital calculations and electronic properties of 2,3-di(2-pyridyl)naphtho[2,3-f]quinoxaline-7,12-quinone (Aqdpp). J Chem Soc Perkin Trans 2 (1998) 877-883
13. Masters C.L., Simms G., Weinman N.A., Multhaup G., McDonald B.L., and Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down Syndrome. Proc Natl Acad Sci USA 82 (1985) 4245
14. Nguyen T., Hamby A., and Massa S. Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model. Proc Natl Acad Sci USA 102 (2005) 11840
15. Ritchie C.W., Bush A.I., Mackinnon A., Macfarlane S., Mastwyk M., MacGregor L., et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Aβ amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 60 (2003) 1685
16. Skoog D., and Leary J. Instrumental analysis (1994), McGraw-Hill
17. 4: an ATP-activated ionotropic receptor cloned from rat brain. Proc Natl Acad Sci USA 93 (1996) 3684
18. Takeshi T. Clioquinol's return: cautions from Japan. Science 292 (2001) 2251
19. Treiber C., Simons A., Strauss M., Hafner M., Cappai R., Bayer T.A., et al. Clioquinol mediates copper uptake and counteracts copper efflux activities of the amyloid precursor protein of Alzheimer's disease. J Biol Chem 279 (2004) 51958
20. Varela-Nallar L., Toledo E.M., Larrondo L.F., Cabrol A.L., Martins V.R., and Inestrosa N.C. Induction of cellular prion protein gene expression by copper in neurons Am. J Physiol Cell Physiol 290 (2005) C271
21. White A.R., Du T., Laughton K.M., Volitakis I., Sharples R.A., Xilinas M.E., et al. Degradation of the alzheimer's disease amyloid beta peptide by metal-dependent up-regulation of metalloprotease activity. J Biol Chem 281 (2006) 17670